Cargando…

Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy

Intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy usually starts with a 2.0 g/kg induction dose followed by 1.0 g/kg maintenance doses every 3 weeks. No dose-ranging studies with intravenous immunoglobulin maintenance therapy have been published. The Progress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cornblath, David R, van Doorn, Pieter A, Hartung, Hans-Peter, Merkies, Ingemar S J, Katzberg, Hans D, Hinterberger, Doris, Clodi, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050528/ https://www.ncbi.nlm.nih.gov/pubmed/35038723 http://dx.doi.org/10.1093/brain/awab422

Ejemplares similares

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
por: Cornblath, David R., et al.
Publicado: (2023)

A randomised, multi‐centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol
por: Cornblath, David R., et al.
Publicado: (2018)

Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes
por: Breiner, Ari, et al.
Publicado: (2019)

Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review
por: Lewis, Richard A., et al.
Publicado: (2020)

Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Merkies, Ingemar S. J., et al.
Publicado: (2022)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial
por: van Schaik, Ivo N., et al.
Publicado: (2016)

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
por: Tortorici, Michael A., et al.
Publicado: (2021)

Dose‐dependent inhibition of demyelination and microglia activation by IVIG
por: Winter, Meike, et al.
Publicado: (2016)

Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
por: Adrichem, Max E., et al.
Publicado: (2022)

Electrophysiological Responsiveness to Long-Term Therapy in Chronic Inflammatory Demyelinating Polyneuropathy: Case Report
por: Khomand, Payam, et al.
Publicado: (2020)

The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies
por: Querol, Luis A., et al.
Publicado: (2022)

The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes – An Observational Study
por: Dunnigan, Samantha K., et al.
Publicado: (2014)

Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy
por: Stettner, Mark, et al.
Publicado: (2015)

Temporal Dispersion and Duration of the Distal Compound Muscle Action Potential Do Not Distinguish Diabetic Sensorimotor Polyneuropathy From Chronic Inflammatory Demyelinating Polyneuropathy
por: Alcantara, Monica, et al.
Publicado: (2022)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
por: Blackhouse, Gord, et al.
Publicado: (2010)

Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy
por: Graf, Jonas, et al.
Publicado: (2018)

Comparison of diabetes patients with “demyelinating” diabetic sensorimotor polyneuropathy to those diagnosed with CIDP
por: Dunnigan, Samantha K, et al.
Publicado: (2013)

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
por: Merkies, Ingemar S.J., et al.
Publicado: (2019)

Depression with Chronic Inflammatory Demyelinating Polyneuropathy
por: Marwale, Arun, et al.
Publicado: (2018)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
por: Alsolaihim, Alanood, et al.
Publicado: (2020)

Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post‐hoc analysis of the immunoglobulin overtreatment in CIDP trial
por: van Veen, Robin, et al.
Publicado: (2022)

Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study
por: Masanneck, Lars, et al.
Publicado: (2023)

CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy: Subtle Retinal Changes in Optical Coherence Tomography
por: Ingwersen, Jens, et al.
Publicado: (2021)

Tailoring of therapy for chronic inflammatory demyelinating polyneuropathy
por: Rajabally, Yusuf A.
Publicado: (2015)

Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy
por: Allen, Jeffrey A., et al.
Publicado: (2018)

The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy
por: Bril, Vera, et al.
Publicado: (2016)

Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale
por: Barnett, Carolina, et al.
Publicado: (2015)

Octagam(®) for chronic inflammatory demyelinating polyneuropathy: results from three observational studies
por: Wietek, Stefan
Publicado: (2018)

IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV
por: Reghukumar, Aravind, et al.
Publicado: (2014)

Chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus
por: Fatehi, Farzad, et al.
Publicado: (2013)

Fibrillary glomerulonephritis combined with chronic inflammatory demyelinating polyneuropathy
por: Sung, Woo Kyung, et al.
Publicado: (2015)

Inflammatory demyelinating polyneuropathy after total hip arthroplasty
por: Hess, Shane R., et al.
Publicado: (2018)

Evolving Immunologic Perspectives in Chronic Inflammatory Demyelinating Polyneuropathy
por: Rajabally, Yusuf A, et al.
Publicado: (2020)

Treatment-related fluctuations in subacute inflammatory demyelinating polyneuropathy
por: Min, Young Gi, et al.
Publicado: (2020)

Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy
por: Chaudhary, Umair J., et al.
Publicado: (2020)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Peripheral Nerve Enlargement in Chronic Inflammatory Demyelinating Polyneuropathy
por: Tanitame, Keizo, et al.
Publicado: (2020)

Reversible conduction failure in acute inflammatory demyelinating polyneuropathy
por: Kim, Sooyoung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c55n67kmt5cf2bl6vggentius2